26
|
Tepekoylu C, Graber M, Poelzl L, Hirsch J, Kirchmair E, Degenhart G, Demetz E, Lobenwein D, Lener D, Fuchs C, Feuchtner G, Grimm M, Holfeld J. 39Toll-like receptor 3 mediates the onset of calcific aortic valve disease. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Tepekoylu C, Poelzl L, Graber M, Hirsch J, Lobenwein D, Zipperle J, Blumer M, Kirchmair E, Kirchmair R, Paulus P, Davidson S, Grimm M, Holfeld J. 5921miR-19a-3p containing exosomes improve cardiac function in ischemic myocardium. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.5921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Graber M, Khoueir Z, Beauchet A, Benhatchi N, Hammoud S, Lachkar Y. High intensity focused ultrasound as first line treatment in patients with chronic angle closure glaucoma at risk for malignant glaucoma. J Fr Ophtalmol 2017; 40:264-269. [DOI: 10.1016/j.jfo.2016.10.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Revised: 10/24/2016] [Accepted: 10/26/2016] [Indexed: 10/19/2022]
|
29
|
Charpentier S, Graber M, Rambaud C, Monin J, Berguiga M, Delbarre M, Sendon D, Marechal M, Timsit A, Froussart-Maille F. Implantable Collamer Lens to treat high myopia: efficiency and safety. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Graber M, Challe G, Alexandre MF, Bodaghi B, LeHoang P, Touitou V. Evaluation of the visual function of patients with locked-in syndrome: Report of 13 cases. J Fr Ophtalmol 2016; 39:437-40. [PMID: 27158101 DOI: 10.1016/j.jfo.2016.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2015] [Revised: 12/20/2015] [Accepted: 01/04/2016] [Indexed: 11/19/2022]
Abstract
Although visual function is thought to be preserved in patients with locked-in syndrome (LIS), enabling them to communicate through vertical or lateral eye movements or blinking of the upper eyelid, nothing is known about the actual visual function of patients with LIS. The goal of this study is to evaluate the visual function of patients with LIS which may enable better evaluation of the state of consciousness of these patients. Patients with LIS seen in a single neurovascular unit of a tertiary center between 1997 and 2013 were retrospectively reviewed. Each patient had a specialized neuro-ophthalmological evaluation under optimal environmental conditions (light, contrast, examination distance, head position, best ergonomic adaptation, and establishment of a means of communication with help from the patient's friends/family). Visual acuity, extraocular eye movements, confrontational visual field, slit lamp and fundus examination were performed. Thirteen patients (6M/7F) were included in this study. Mean visual acuity was 20/60. Oculomotor examination was abnormal in 77%. Forty-six percent of patients presented binocular diplopia mainly related to a VIth nerve palsy. One patient presented complete ophthalmoplegia. Forty-six percent of patients had nystagmus responsible for oscillopsia (oculopalatal tremor). An abnormal visual field was observed in 17% of patients, and abnormal pupillary light response leading to photophobia was present in 22% of patients. Keratitis or dry eye syndrome was present in most patients and was a major cause of pain and visual impairment. Our results suggest that the visual function is impaired in all patients with LIS. This impairment is multifactorial including mostly binocular diplopia or oscillopsia but also refractive errors, dry eye syndrome, keratitis or visual field defect. This altered visual function may alter the ability of the patient to interact with his environment and lead to underestimation of their state of consciousness. An ophthalmologic evaluation would allow for improvement of these patients' comfort, their ability to communicate, and the assessment of their state of consciousness.
Collapse
|
31
|
Graber M, Glacet-Bernard A, Fardeau C, Massamba N, Atassi M, Rostaqui O, Coscas F, Le Hoang P, Souied EH. [Comparison of early management of central retinal vein occlusion with ranibizumab versus hemodilution]. J Fr Ophtalmol 2015; 38:815-21. [PMID: 26456487 DOI: 10.1016/j.jfo.2015.03.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/18/2015] [Accepted: 03/02/2015] [Indexed: 11/29/2022]
Abstract
PURPOSE This study was designed to evaluate and compare the efficacy of early treatment of CRVO with either hemodilution by erythrocytopheresis or intravitreal (IVT) ranibizumab, or both. MATERIAL AND METHODS A multicentric prospective randomized study including patients with CRVO for less than 1 month was designed. Patients were randomized into 3 treatment groups: hemodilution (HD group), 3 monthly intravitreal injections of ranibizumab followed by PRN treatment (IVT group), or combined treatment (IVT+HD group). A monthly evaluation during a 6-month follow-up included best-corrected visual acuity (BCVA) and macular thickness measurements with OCT. Fluorescein angiography was performed at baseline, month 2 and month 6. Local and systemic tolerability of the different treatments were also compared. RESULTS Forty-four CRVO patients were included between February 2010 and June 2013: 20 in the IVT group, 13 in the HD group and 11 in the HD+IVT group. The mean duration of CRVO at baseline was 10 days and 16 days at the time of treatment without any significant difference between groups. Retinal ischemia was present at baseline in 40% of eyes in each group. After a 6-month follow-up, no difference between the 3 groups was observed in BCVA (10.5 ETDRS letters, 14.6 and 14.1 in the IVT group, HD group and IVT+HD group respectively, P=0.726) or in macular thickness (398 μ, 440 μ and 379 μ respectively, P=0.465). The time until treatment from CRVO onset, ranging from 1 to 35 days, was not correlated to final outcomes. No significant difference in the mean number of IVT (3.2 in the IVT+HD group vs 3.7 in the IVT group) was observed at 6 months. CONCLUSION No difference in BCVA nor in macular thickness was seen at M6 between the study groups. The duration of CRVO at the time of the initiation of the treatment was not correlated to better visual outcomes. Therefore, etiologic treatment with HD can still be proposed as a first-line treatment in young patients, which allows delaying or avoiding the IVT treatment and its potential side effects. Anti-VEGF IVT still remains an effective option in every case and can be started one month after the beginning of the CRVO.
Collapse
|
32
|
Sendon D, Graber M, Chiche A, Rambaud C, Berguiga M, Delbarre M, Froussart-Maille F. Oral eplerenone as a first line treatment in chronic central serous chorioretinopathy: A case series evaluation. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Delbarre M, Rambaud C, Berguiga M, Sendon D, Graber M, Froussart-Maille F. Evaluation of the influence of corneal biomechanical properties on the central corneal curvature after a SUPRACOR procedure. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Pai J, Chiu W, Shultz D, Graber M, Columbo L, Wild A, Kumar R, Herman J, Chang D, Koong A. Plasma SPARC Following Stereotactic Body Radiation Therapy (SBRT) Predicts for Progression-Free Survival in Locally-Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
van Dorland HA, Graber M, Kohler S, Steiner A, Bruckmaier RM. Comparison of hepatic adaptation in extreme metabolic phenotypes observed in early lactation dairy cows on-farm. J Anim Physiol Anim Nutr (Berl) 2013; 98:693-703. [DOI: 10.1111/jpn.12125] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2013] [Accepted: 08/07/2013] [Indexed: 11/27/2022]
|
36
|
Chaput L, Sanejouand YH, Balloumi A, Tran V, Graber M. Contribution of both catalytic constant and Michaelis constant to CALB enantioselectivity: Use of FEP calculations for prediction studies. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/j.molcatb.2011.11.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Stadlbauer U, Arnold M, Graber M, Langhans W. Hepatic portal vein (HPV) peptide tyrosine-tyrosine (PYY) and meal-taking in rats. Appetite 2011. [DOI: 10.1016/j.appet.2011.05.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Graber M, Kohler S, Müller A, Burgermeister K, Kaufmann T, Bruckmaier RM, van Dorland HA. Identification of plasma and hepatic parameters related to metabolic robustness in dairy cows. J Anim Physiol Anim Nutr (Berl) 2011; 96:75-84. [DOI: 10.1111/j.1439-0396.2010.01124.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Graber M, Kohler S, Kaufmann T, Doherr M, Bruckmaier R, van Dorland H. A field study on characteristics and diversity of gene expression in the liver of dairy cows during the transition period. J Dairy Sci 2010; 93:5200-15. [DOI: 10.3168/jds.2010-3265] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2010] [Accepted: 07/08/2010] [Indexed: 01/23/2023]
|
40
|
Graber M, Rucker E, Chavez E, Thompson K, Ortiz M. 334: Arm Circumference for a Rapid Estimate of Emergency Patient Weight. Ann Emerg Med 2010. [DOI: 10.1016/j.annemergmed.2010.06.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Marton Z, Léonard-Nevers V, Syrén PO, Bauer C, Lamare S, Hult K, Tranc V, Graber M. Mutations in the stereospecificity pocket and at the entrance of the active site of Candida antarctica lipase B enhancing enzyme enantioselectivity. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.molcatb.2010.01.007] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Pacheco-López G, Punjabi M, Graber M, Geary N, Arnold M, Langhans W. Hindbrain glucagon-like peptide-1 receptors (GLP-1R) mediate the eating-inhibitory effect of hepatic portal vein (HPV) GLP-1 infusions. Appetite 2010. [DOI: 10.1016/j.appet.2010.04.158] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Feinberg E, Graber M, Jasulaitis S, Jacobs L, Byers M, Beltsos A. Comparison of clinical pregnancy rates in programmed frozen embryo transfer cycles between endometrin and progesterone in oil. Fertil Steril 2009. [DOI: 10.1016/j.fertnstert.2009.07.1284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest 2006; 24:388-404. [PMID: 16695228 PMCID: PMC435470 DOI: 10.1172/jci101618] [Citation(s) in RCA: 1272] [Impact Index Per Article: 70.7] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
45
|
Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, McNealy K, Schilling L. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 2005; 2005:CD003697. [PMID: 16235336 PMCID: PMC11102950 DOI: 10.1002/14651858.cd003697.pub2] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Effective treatment for advanced melanoma is lacking. While no drug therapy currently exists for prevention of melanoma, in vitro, case-control, and animal model evidence suggest that lipid-lowering medications, commonly taken for high cholesterol, might prevent melanoma. OBJECTIVES To assess the effects of statin or fibrate lipid-lowering medications on melanoma outcomes. SEARCH STRATEGY We searched the Cochrane Skin Group Specialised Register (February 2003), CENTRAL (The Cochrane Library Issue 1, 2005), MEDLINE (to March 2003), EMBASE (to September 2003), CANCERLIT (to October 2002), Web of Science (to May 2003), and reference lists of articles. We approached study investigators and pharmaceutical companies for additional information (published or unpublished studies). SELECTION CRITERIA Trials involving random allocation of study participants, where experimental groups used statins or fibrates and participants were enrolled for at least four years of therapy. DATA COLLECTION AND ANALYSIS Three authors screened 109 abstracts of articles with titles of possible relevance. We then thoroughly examined the full text of 72 potentially relevant articles. We requested unpublished melanoma outcomes data from the corresponding author of each qualifying trial. MAIN RESULTS We identified 16 qualifying randomised controlled trials (RCTs) (seven statin, nine fibrate). Thirteen of these trials (involving 62,197 participants) provided data on incident melanomas (six statin, seven fibrate). A total of 66 melanomas were reported in groups receiving the experimental drug and 86 in groups receiving placebo or other control therapies. For statin trials this translated to an odds ratio of 0.90 (95% confidence interval 0.56 to 1.44) and for fibrate trials an odds ratio of 0.58 (95% confidence interval 0.19 to 1.82). Subgroup analyses failed to show statistically significant differences in melanoma outcomes by gender, melanoma occurrence after two years of participation in trial, stage or histology, or trial funding. Subgroup analysis by type of fibrate or statin also failed to show statistically significant differences, except for the statin subgroup analysis which showed reduced melanoma incidence for lovastatin, based on one trial only (odds ratio 0.52, 95% confidence interval 0.27 to 0.99). AUTHORS' CONCLUSIONS The melanoma outcomes data collected in this review of RCTs of statins and fibrates does not exclude the possibility that these drugs prevent melanoma. There was a 10% and 42% reduction for participants on statins and fibrates, respectively, however these results were not statistically significant. Until further evidence is established, limiting exposure to ultraviolet radiation remains the most effective way to reduce the risk of melanoma.
Collapse
|
46
|
Dellavalle R, McNealy K, Graber M, Morelli J, Schilling L. Lipid-lowering agents for preventing melanoma. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2002. [DOI: 10.1002/14651858.cd003697] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
47
|
Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. MAGNESIUM RESEARCH 2001; 14:257-62. [PMID: 11794633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Magnesium deficiency is seen with some frequency in the outpatient setting and requires oral repletion or maintenance therapy. The purpose of this study was to measure the bioavailability of four commercially-available preparations of magnesium, and to test the claim that organic salts are more easily absorbed. Bioavailability was measured as the increment of urinary maginesium excretion in normal volunteers given approximately 21 mEq/day of the test preparations. Results indicated relatively poor bioavailability of magnesium oxide (fractional absorption 4 per cent) but significantly higher and equivalent bioavailability of magnesium chloride, magnesium lactate and magnesium aspartate. We conclude that there is relatively poor bioavailability of magnesium oxide, but greater and equivalent bioavailability of magnesium chloride, lactate, and aspartate. Inorganic magnesium salts, depending on the preparation, may have bioavailability equivalent to organic magnesium salts.
Collapse
|
48
|
Bousquet-Dubouch MP, Graber M, Sousa N, Lamare S, Legoy MD. Alcoholysis catalyzed by Candida antarctica lipase B in a gas/solid system obeys a Ping Pong Bi Bi mechanism with competitive inhibition by the alcohol substrate and water. BIOCHIMICA ET BIOPHYSICA ACTA 2001; 1550:90-9. [PMID: 11738091 DOI: 10.1016/s0167-4838(01)00273-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The kinetics of alcoholysis of methyl propionate and n-propanol catalyzed by Candida antarctica lipase B supported onto silanized Chromosorb P was studied in a continuous solid/gas reactor. In this system the solid phase is composed of a packed enzymatic sample and is percolated by nitrogen as carrier gas, which simultaneously carries substrates to the enzyme while removing reaction products. In this reactor the thermodynamic activity of substrates and effectors can be perfectly adjusted allowing kinetic studies to be performed under different operating conditions. The kinetics obtained for alcoholysis were suggested to fit a Ping Pong Bi Bi mechanism with dead-end inhibition by the alcohol. The values of all apparent kinetic parameters were calculated and the apparent dissociation constant of enzyme for gaseous ester was found very low compared with the one obtained for liquid ester in organic medium, certainly due to the more efficient diffusion in the gaseous phase. The effect of water thermodynamic activity was also investigated. Water was found to act as a competitive inhibitor, with a higher inhibition constant than n-propanol. Thus alcoholysis of gaseous methyl propionate and n-propanol catalyzed by C. antarctica lipase B was found to obey the same kinetic mechanism as in other non-conventional media such as organic liquid media and supercritical carbon dioxide, but with much higher affinity for the substrates.
Collapse
|
49
|
van Zuuren EJ, Powell FC, Graber M. Interventions for acne rosacea. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2000. [DOI: 10.1002/14651858.cd003262] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
50
|
Gaillard-Gendron S, Vignon D, Cottenceau G, Graber M, Zorn N, van Dorsselaer A, Pons AM. Isolation, purification and partial amino acid sequence of a highly hydrophobic new microcin named microcin L produced by Escherichia coli. FEMS Microbiol Lett 2000; 193:95-8. [PMID: 11094285 DOI: 10.1111/j.1574-6968.2000.tb09408.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
We report here the production, by an Escherichia coli strain, of two microcins, microcin J25 and a new one that we designated microcin L. The active peptides were separated by solid phase extraction on C(18) cartridges. Microcin L was then purified to homogeneity by cationic-exchange high-performance liquid chromatography. Its molecular mass, determined by mass spectrometry, is 8899 Da. The amino acid composition and the sequence of the first 40 N-terminal residues indicate that microcin L is a hydrophobic peptide, which exhibits high homology to gassericin and lactacin F which both belong to the class II bacteriocins.
Collapse
|